We collaborated with St George’s, University of London, on a NIHR-funded ‘Test n Treat’ (TnT) study. This study assessed the cost of providing same-day chlamydia and gonorrhoea testing and treatment service at higher education colleges. The paper presenting this work was published in BMC Health Services Research and is now available online.Continue reading
The results of our economic evaluation comparing the use of mRNA and DNA assays in screening for cervical cancer in England were published in BMJ Open and are now available online. Results show large cost savings from avoiding unnecessary testing and follow-up, which can benefit women and healthcare services.Continue reading
We’re delighted to welcome Shona and Ben to the Aquarius team.Continue reading
We’re pleased to have welcomed two new members of the Aquarius team since moving to our new office in Tileyard in 2018.
Georgie Weston joined the team in October as an Associate, having recently completed her Master of Public Health at the London School of Hygiene and Tropical Medicine, awarded with Distinction. Georgie has experience working with a range of organisations, including the WHO, health charities, and large pharmaceutical companies where she worked within communications and marketing strategy.Continue reading
Aquarius were part of a recent feasibility trial looking at whether provision of a same day test and treatment service for chlamydia in further education colleges increased uptake of chlamydia testing and treatment. The results of the trial were published this week in Clinical Microbiology and Infection and are available online.
New point-of-care (POC) tests are currently being developed which can be used in clinic to simultaneously test for multiple sexually transmitted infections (STIs). In work now published online in BMJ Open, we developed a model to compare three possible strategies for POC STI testing with the current practice of microscopy and lab-based testing. The three strategies were: 1) a dual test for chlamydia and gonorrhoea; 2) a triple test which also tests for M. genitalium, and 3) a quadruple test which also tested for trichomoniasis. The model examined the overall costs, patient benefits and cost-effectiveness of these strategies. The full results of the economic evaluation including the article and supplementary material are available online.
An article authored by Aquarius was published today on the British In Vitro Diagnostics Association (BIVDA) website. The article commissioned jointly by BIVDA and Innovate UK suggests that the NHS could save over £6.9 billion in 5 years by making better use of diagnostic tests already on the market. These savings could have a huge impact in reducing the annual NHS shortfall, which is expected to be £20 billion by 2022.
At Aquarius, we love an opportunity to learn new skills and work together as a team to produce something we’re proud of. Our team away day was no exception. In an 800-acre forest in the depths of West Sussex, we spent the day in our outdoor gear learning some bush craft and how we can achieve our business strategy in the coming year.
The winter flu season brings added pressure to emergency and acute hospital services. In the UK, children and infants account for more than a third of flu related hospital admissions since flu and respiratory syncytial viruses (RSV) can be particularly severe in children, particularly those with existing conditions such as asthma.
In our recent paper published, we report the results of a real-world evaluation conducted in a busy children’s hospital in central London. We assessed the impact and economic benefits of using a 90-minute point-of-care (POC) assay to test for influenza and RSV in children and infants admitted to hospital. This was done by comparing data collected from an acute paediatric ward during one flu season, when standard laboratory testing was used, with data collected from the same ward in the subsequent flu season, when the POC test was in use.